| Upcoming events on ALNYLAM PHARMACEUTICALS, INC. |
|
| 02/11/21 | | Jahr 2020 Ergebnisveröffentlichung (geplant) |
| 05/06/21 | | Q1 2021 Ergebnisveröffentlichung (geplant) |
| 08/12/21 | | Erstes Halbjahr 2021 Ergebnisveröffentlichung (geplant) |
| 11/10/21 | | Q3 2021 Ergebnisveröffentlichung (geplant) |
|
| Past events on ALNYLAM PHARMACEUTICALS, INC. |
|
| 01/11/21 | 02:20pm | | JP Morgan Healthcare Conference |
| 01/07/21 | 02:00pm | | Vutrisiran HELIOS-A Phase 3 Study Results Call |
| 12/16/20 | 03:00pm | | R&D Day - Day - 2 |
| 12/15/20 | 03:00pm | | R&D Day - Day - 1 |
|
| Upcoming sector events for ALNYLAM PHARMACEUTICALS, INC. |
|
|
| |
|
| Past sector events for ALNYLAM PHARMACEUTICALS, INC. |
|
|
|
|
|
| Annual results | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 (e) |
Sales
M $ |
Released
Forecast
Spread | 41,1
39,5
3,9% | 47,2
41,9
13% | 89,9
72,2
25% | 74,9
68,0
10% | 220
221
-0,43% |
476
|
Operating income
(EBITDA)
M $ |
Released
Forecast
Spread | -277
-276
-0,46% | -409
-412
0,67% | -487
-461
-5,5% | -808
-736
-9,8% | -885
-857
-3,3% |
-786
|
Operating profit
(EBIT)
M $ |
Released
Forecast
Spread | -296
-280
-5,8% | -425
-423
-0,48% | -500
-484
-3,3% | -815
-824
1,1% | -939
-893
-5,2% |
-836
|
Pre-Tax Profit
(EBT)
M $ |
Released
Forecast
Spread | -290
-276
-5,2% | -410
-404
-1,5% | -491
-481
-2,1% | -761
-781
2,6% | -885
-853
-3,8% |
-823
|
Net income
M $ |
Released
Forecast
Spread | -290
-277
-4,7% | -410
-410
-0,06% | -491
-479
-2,4% | -761
-780
2,3% | -886
-860
-3,1% |
-829
|
EPS
$ |
Released
Forecast
Spread | -3,45
-3,28
-5,1% | -4,79
-4,79
0,07% | -5,42
-5,30
-2,3% | -7,57
-7,76
2,4% | -8,11
-7,93
-2,2% |
-7,09
| | Announcement Date | 02/11/2016 | 02/08/2017 | 02/08/2018 | 02/07/2019 | 02/06/2020 | |
|
|
|
| Quarterly results | 2018 Q2 | 2018 Q3 | 2018 Q4 | 2019 Q1 | 2019 Q2 | 2019 Q3 | 2019 Q4 | 2020 Q1 | 2020 Q2 | 2020 Q3 | 2020 Q4 (e) | 2021 Q1 (e) | 2021 Q2 (e) | 2021 Q3 (e) | 2021 Q4 (e) |
Sales
M $ |
Released
Forecast
Spread | 29,9
17,0
76% | 2,07
22,7
-91% | 21,0
15,0
40% | 33,3
21,6
54% | 44,7
42,5
5,1% | 70,1
57,1
23% | 71,7
71,1
0,75% | 99,5
90,5
10,0% | 104
98,8
5,3% | 126
119
5,7% |
148
|
154
|
184
|
201
|
232
|
Operating income
(EBITDA)
M $ |
Released
Forecast
Spread |
|
|
|
|
|
|
| -193
-213
9,4% | -191
-145
-32% | -217
-179
-21% |
-162
|
-167
|
-147
|
-128
|
-108
|
Operating profit
(EBIT)
M $ |
Released
Forecast
Spread | -192
-187
-2,6% | -255
-209
-22% | -220
-231
4,4% | -189
-232
19% | -236
-241
1,8% | -216
-240
9,9% | -298
-251
-19% | -210
-220
4,3% | -199
-204
2,3% | -225
-192
-17% |
-202
|
-195
|
-179
|
-168
|
-145
|
Pre-Tax Profit
(EBT)
M $ |
Released
Forecast
Spread | -163
-183
11% | -245
-204
-20% | -211
-228
7,5% | -181
-225
19% | -219
-234
6,5% | -209
-236
11% | -277
-238
-16% | -182
-214
15% | -178
-206
14% | -252
-200
-26% |
-208
|
-210
|
-197
|
-188
|
-175
|
Net income
M $ |
Released
Forecast
Spread | -164
-180
9,3% | -245
-205
-20% | -211
-221
4,1% | -182
-222
18% | -219
-237
7,5% | -209
-234
11% | -276
-248
-12% | -182
-211
14% | -179
-200
10% | -253
-192
-32% |
-205
|
-208
|
-196
|
-188
|
-177
|
EPS
$ |
Released
Forecast
Spread | -1,63
-1,79
9,0% | -2,43
-1,98
-23% | -2,09
-2,23
6,1% | -1,73
-2,16
20% | -2,02
-2,16
6,5% | -1,92
-2,10
8,7% | -2,47
-2,22
-11% | -1,62
-1,87
13% | -1,56
-1,79
13% | -2,18
-1,64
-33% |
-1,72
|
-1,72
|
-1,58
|
-1,55
|
-1,47
| | Announcement Date | 08/02/2018 | 11/07/2018 | 02/07/2019 | 05/01/2019 | 08/06/2019 | 10/31/2019 | 02/06/2020 | 05/06/2020 | 08/06/2020 | 11/05/2020 | | | | | |
|
Financial data source
© 2021 S&P Global Market Intelligence
|
|
© 2021 Factset
|
|
|
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
Previous period
